Quarterly report · Q3
9265.TEDINET S100QJ7N
Period2022-06-01 → 2023-02-28
Filed2023-04-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥41.7bn | 2022-06-01 → 2023-02-28 | Cons. | Net sales |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥40.6bn | 2021-06-01 → 2022-02-28 | Cons. | Net sales |
| Operating income | ¥895m | 2022-06-01 → 2023-02-28 | Cons. | Operating income |
| Operating income | ¥852m | 2021-06-01 → 2022-02-28 | Cons. | Operating income |
| Ordinary income | ¥936m | 2022-06-01 → 2023-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥907m | 2021-06-01 → 2022-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥333m | 2022-06-01 → 2023-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥923m | 2021-06-01 → 2022-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥1m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥592m | 2021-06-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥3m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss |
| Net income | ¥591m | 2021-06-01 → 2022-02-28 | Cons. | Profit loss |
| Total assets | ¥22.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥24.1bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥23.9bn | at 2022-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.8bn | at 2023-02-28 | Cons. | Liabilities |
| Total liabilities | ¥16.1bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.7bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2022-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥0.46 | 2022-06-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥79.44 | 2022-12-01 → 2023-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥232.03 | 2021-06-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.21 | 2021-12-01 → 2022-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.2% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-02-28 | −¥11m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-02-28 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-02-28 | −¥690m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥211m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥211m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥0 |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥41.5bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥41.5bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥11m |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥1.6bn |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥50m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥50m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥0 |
| —segment total | revenue | 2022-06-01 → 2023-02-28 | ¥41.7bn |
| —segment total | revenue external | 2022-06-01 → 2023-02-28 | ¥41.7bn |
| —segment total | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥11m |
| —segment total | segment profit | 2022-06-01 → 2023-02-28 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2022-02-28 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2022-02-28 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-02-28 | −¥658m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥214m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥214m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2021-06-01 → 2022-02-28 | ¥0 |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2021-06-01 → 2022-02-28 | ¥12m |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥40.4bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥40.4bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2021-06-01 → 2022-02-28 | ¥0 |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2021-06-01 → 2022-02-28 | ¥1.5bn |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥51m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥51m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | segment profit | 2021-06-01 → 2022-02-28 | −¥7m |
| —segment total | revenue | 2021-06-01 → 2022-02-28 | ¥40.6bn |
| —segment total | revenue external | 2021-06-01 → 2022-02-28 | ¥40.6bn |
| —segment total | revenue intersegment | 2021-06-01 → 2022-02-28 | ¥0 |
| —segment total | segment profit | 2021-06-01 → 2022-02-28 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 360
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |